Stock Events

Stock Events

Kronos Bio 

$0.8800
11
+$0.01+1.49% Friday 20:00

Statistics

Day High
0.881
Day Low
0.8701
52W High
1.46
52W Low
0.65
Volume
53,687
Avg. Volume
855,959
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

7AugExpected
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
-0.52
-0.42
-0.33
-0.23
Expected EPS
-0.3
Actual EPS
N/A

Financials

-874.08%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
9.85MRevenue
-86.08MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a leading biopharmaceutical company that competes with Kronos Bio in the development of novel cancer therapies, particularly in the area of small molecule drugs.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotechnology giant that develops innovative human therapeutics, including cancer treatments that directly compete with Kronos Bio's oncology pipeline.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is known for its strong portfolio in antiviral drugs but also competes in the oncology space, making it a direct competitor to Kronos Bio in cancer treatment research.
Merck
MRK
Mkt Cap366B
Merck & Co. is a global healthcare company that develops cancer treatments, including immunotherapy and targeted therapy drugs, competing with Kronos Bio's approach to cancer treatment.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a pharmaceutical corporation with a broad range of healthcare products, including cancer treatments that compete with Kronos Bio's research and development in oncology.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that offers a wide range of healthcare products, including innovative medicines in oncology, directly competing with Kronos Bio's cancer therapy research.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie is a biopharmaceutical company that has a strong focus on research-based pharmaceuticals, including oncology, making it a competitor to Kronos Bio in the development of cancer treatments.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company is a global pharmaceutical company that develops a wide range of medicines, with a focus on oncology, competing with Kronos Bio in cancer research and treatment.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its innovative medicines for serious medical conditions, including oncology, positioning it as a competitor to Kronos Bio in the field of cancer treatment.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including for oncology, making it a direct competitor to Kronos Bio in cancer therapy research.

About

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Show more...
CEO
Dr. Deborah A. Knobelman Ph.D.
Employees
8
Country
United States
ISIN
US50107A1043

Listings

0 Comments

Share your thoughts

FAQ

What is Kronos Bio stock price today?▼
The current price of KRON is $0.88 USD — it has increased by +1.49% in the past 24 hours. Watch Kronos Bio stock price performance more closely on the chart.
What is Kronos Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Kronos Bio stocks are traded under the ticker KRON.
What is Kronos Bio revenue for the last year?▼
Kronos Bio revenue for the last year amounts to 9.85M USD.
What is Kronos Bio net income for the last year?▼
KRON net income for the last year is -86.08M USD.
How many employees does Kronos Bio have?▼
As of September 04, 2026, the company has 8 employees.
In which sector is Kronos Bio located?▼
Kronos Bio operates in the Health & Wellness sector.
When did Kronos Bio complete a stock split?▼
The last stock split for Kronos Bio was on November 03, 2003 with a ratio of 3:2.
Where is Kronos Bio headquartered?▼
Kronos Bio is headquartered in San Mateo, United States.